These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20477424)

  • 21. Olfactory dysfunction in Parkinson's disease.
    Kranick SM; Duda JE
    Neurosignals; 2008; 16(1):35-40. PubMed ID: 18097158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. When does Parkinson's disease begin?
    Gaig C; Tolosa E
    Mov Disord; 2009; 24 Suppl 2():S656-64. PubMed ID: 19877243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress.
    Mila S; Albo AG; Corpillo D; Giraudo S; Zibetti M; Bucci EM; Lopiano L; Fasano M
    Biomark Med; 2009 Apr; 3(2):117-28. PubMed ID: 20477505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease.
    Hatano T; Kubo S; Sato S; Hattori N
    J Neurochem; 2009 Dec; 111(5):1075-93. PubMed ID: 19780902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease.
    Michell AW; Luheshi LM; Barker RA
    Neurosci Lett; 2005 Jun; 381(3):294-8. PubMed ID: 15896487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation between subtype of Parkinson's disease and REM sleep behavior disorder.
    Kumru H; Santamaria J; Tolosa E; Iranzo A
    Sleep Med; 2007 Nov; 8(7-8):779-83. PubMed ID: 17904419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
    Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
    Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Progress in the basic and clinical aspects of Parkinson's disease].
    Mizuno Y
    Rinsho Shinkeigaku; 2004 Nov; 44(11):741-50. PubMed ID: 15651281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pathophysiological basis of sensory disturbances in Parkinson's disease.
    Juri C; Rodriguez-Oroz M; Obeso JA
    J Neurol Sci; 2010 Feb; 289(1-2):60-5. PubMed ID: 19758602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease: 10 years of progress, 1997-2007.
    Fahn S
    Mov Disord; 2010; 25 Suppl 1():S2-14. PubMed ID: 20187239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography.
    Dhawan V; Dhoat S; Williams AJ; Dimarco A; Pal S; Forbes A; Tobías A; Martinez-Martin P; Chaudhuri KR
    J Neurol Sci; 2006 Oct; 248(1-2):158-62. PubMed ID: 16780888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
    McFarlane D
    Ageing Res Rev; 2007 May; 6(1):54-63. PubMed ID: 17374512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging the impact of genes on Parkinson's disease.
    van der Vegt JP; van Nuenen BF; Bloem BR; Klein C; Siebner HR
    Neuroscience; 2009 Nov; 164(1):191-204. PubMed ID: 19409223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free radicals in Parkinson's disease.
    Koutsilieri E; Scheller C; Grünblatt E; Nara K; Li J; Riederer P
    J Neurol; 2002 Sep; 249 Suppl 2():II1-5. PubMed ID: 12375056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies.
    Alberio T; Fasano M
    J Biotechnol; 2011 Dec; 156(4):325-37. PubMed ID: 21925549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spectroscopy of human plasma for diagnosis of idiopathic Parkinson's disease.
    Schipper HM; Kwok CS; Rosendahl SM; Bandilla D; Maes O; Melmed C; Rabinovitch D; Burns DH
    Biomark Med; 2008 Jun; 2(3):229-38. PubMed ID: 20477412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?
    Chahine LM; Stern MB
    Mov Disord Clin Pract; 2017; 4(6):796-805. PubMed ID: 30363472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.